Showing 3481-3490 of 5621 results for "".
- Cost, Purchase Factors, and Correct Usage Drive Online Contact Lens Searcheshttps://modernod.com/news/cost-purchase-factors-and-correct-usage-drive-online-contact-lens-searches-according-to-new-research-in-the-us-and-canada/2482671/New research from the Contact Lens Institute (CLI) demonstrates that purchase factors–specificly contact lens retailers and price–are the primary driver of consumer online contact lens-related searches, representing 65% of top 20 searches in the United States and Canada. Oth
- Oculus Launches Myopia Software Package on the Pentacam AXL Wavehttps://modernod.com/news/oculus-launches-myopia-software-package-on-the-pentacam-axl-wave/2482670/Oculus is launching the Myopia Software Package on the Pentacam AXL Wave. The new software is designed to offer optometrists improved accuracy, ease, and safety in their myopia management, comprehensive screening, and ortho-k fitting with one device. The Pentacam AXL
- Alcon Announces US Launch of Voyager DSLT for Glaucoma and Ocular Hypertensionhttps://modernod.com/news/alcon-announces-us-launch-of-voyager-dslt-for-glaucoma-and-ocular-hypertension/2482669/Alcon announced the full US commercial availability of Voyager DSLT, the first and only direct selective laser trabeculoplasty device (DSLT). According to Alcon, Voyager DSLT may accelerate the adoption of laser as a first-line therapy, making the treatment availabil
- FDA Clears New World Medical's VIA360 Surgical Systemhttps://modernod.com/news/fda-clears-new-world-medicals-via360-surgical-system/2482667/New World Medical has received 510(k) clearance from the FDA for its VIA360 Surgical System for the delivery of controlled amounts of viscoelastic fluid during ophthalmic surgeries. The VIA360, which is also indicated to cut trabecular meshwork tissue during trabecul
- EssilorLuxottica Acquires Canadian Med-Tech Start-Up Cellviewhttps://modernod.com/news/essilorluxottica-acquires-canadian-med-tech-start-up-cellview/2482659/EssilorLuxottica has acquired Cellview Imaging, a Canadian start-up specializing in diagnostic via retinal imaging. Financial terms of the deal were not disclosed. Based in Toronto, Cellview designs and manufactures diagnostic imaging instruments. Currently distributed in North Ame
- TECLens Secures $9.3 Million Series A Funding to Advance Its Noninvasive Refractive Technologyhttps://modernod.com/news/teclens-secures-93-million-series-a-funding-to-advance-its-noninvasive-refractive-technology/2482658/TECLens announced it raised $9.3 million in a Series A round to support the clinical development of the company’s non-incisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea. The funding round was co-led by Johnson &
- DigitalOptometrics to Preview 'World’s First Autonomous Slitlamp' at Vision Expo East 2025https://modernod.com/news/digitaloptometrics-to-preview-worlds-first-autonomous-slitlamp-at-vision-expo-east-2025/2482655/DigitalOptometrics has announced the launch of what it is calling the world’s first and most advanced autonomous slitlamp with remote control capabilities at Vision Expo East (VEE) 2025 in Orlando. In collaboration with SlitLED, DigitalOptometrics will demonstrate t
- 4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Studyhttps://modernod.com/news/4dmt-presents-positive-52-week-results-from-phase-2b-cohort-of-prism-wet-amd-study/2482654/4D Molecular Therapeutics (4DMT) announced positive initial interim 52-week data from the phase 2b population extension cohort of the PRISM clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (AMD) patient population. Additional data were provided on the durabili
- Bausch + Lomb: No Immediate Plans to Go Privatehttps://modernod.com/news/bausch-lomb-no-immediate-plans-to-go-private/2482653/After exploring options to separate from Bausch Health, Bausch + Lomb announced Thursday it decided not to engage in a sale. “Taking Bausch + Lomb private with a third-party buyer was one of several options being explored to complete a full separation from Bausch Health Companies
- Pykus Therapeutics to Present Initial Clinical Data on Novel Retinal Sealanthttps://modernod.com/news/pykus-therapeutics-to-present-initial-clinical-data-on-novel-retinal-sealant/2482651/Pykus Therapeutics announced that it will present initial clinical data on its investigational retinal sealant, PYK-2101, to replace gas and oil during retinal detachment repair. The data will be presented at the Vail Vitrectomy 2025 Meeting on February 10, 2025. The presentat